Drug resistance in Cryptococcus neoformans

被引：82
作者：
Perfect, JR [1 ]
Cox, GM [1 ]
机构：
[1] Duke Univ, Med Ctr, Dept Med, Div Infect Dis, Durham, NC 27710 USA
来源：
DRUG RESISTANCE UPDATES | 1999年 / 2卷 / 04期
关键词：
D O I：
10.1054/drup.1999.0090
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
Cryptococcus neoformans has become a major opportunistic fungal pathogen worldwide. Successful treatment of invasive disease with this fungus has used amphotericin B, flucytosine and various azoles. However, treatment failures continue to occur for a variety of reasons including direct antifungal drug resistance. Issues and mechanisms for antifungal drug resistance in Cryptococcus neoformans are reviewed. Furthermore, approaches and strategies for prevention and treatment of antifungal drug resistance are identified and these include host immune modulation, dose optimization, prophylaxis/empirical regimens, improved drug delivery systems such as lipid preparations of amphotericin B, surgery, combination antifungal treatments and development of new antifungal agents. (C) 1999 Harcourt Publishers Ltd.
引用
收藏
页码：259 / 269
页数：11
相关论文
共 126 条
[21]   Antibody-based therapies for emerging infectious diseases [J].
Casadevall, A .
EMERGING INFECTIOUS DISEASES, 1996, 2 (03) :200-208
[22]  
CHEN GH, 1994, J IMMUNOL, V152, P724
[23]   INFECTIONS WITH CRYPTOCOCCUS-NEOFORMANS IN THE ACQUIRED IMMUNODEFICIENCY SYNDROME [J].
CHUCK, SL ;
SANDE, MA .
NEW ENGLAND JOURNAL OF MEDICINE, 1989, 321 (12) :794-799
[24]  
CLANCY C, 1997, 37 INT C ANT AG CHEM
[25]   AMPHOTERICIN-B LIPID COMPLEX THERAPY OF EXPERIMENTAL FUNGAL-INFECTIONS IN MICE [J].
CLARK, JM ;
WHITNEY, RR ;
OLSEN, SJ ;
GEORGE, RJ ;
SWERDEL, MR ;
KUNSELMAN, L ;
BONNER, DP .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1991, 35 (04) :615-621
[26]   CYTOKINE TREATMENT OF CENTRAL-NERVOUS-SYSTEM INFECTION - EFFICACY OF INTERLEUKIN-12 ALONE AND SYNERGY WITH CONVENTIONAL ANTIFUNGAL THERAPY IN EXPERIMENTAL CRYPTOCOCCOSIS [J].
CLEMONS, KV ;
BRUMMER, E ;
STEVENS, DA .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1994, 38 (03) :460-464
[27]   Comparison of Fungizone, Amphotec, AmBisome, and Abelcet for treatment of systemic murine cryptococcosis [J].
Clemons, KV ;
Stevens, DA .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1998, 42 (04) :899-902
[28]   TREATMENT OF CRYPTOCOCCOSIS WITH LIPOSOMAL AMPHOTERICIN-B (AMBISOME) IN 23 PATIENTS WITH AIDS [J].
COKER, RJ ;
VIVIANI, M ;
GAZZARD, BG ;
DUPONT, B ;
POHLE, HD ;
MURPHY, SM ;
ATOUGUIA, J ;
CHAMPALIMAUD, JL ;
HARRIS, JRW .
AIDS, 1993, 7 (06) :829-835
[29]   CYTOKINE ENHANCEMENT OF COMPLEMENT-DEPENDENT PHAGOCYTOSIS BY MACROPHAGES - SYNERGY OF TUMOR-NECROSIS-FACTOR-ALPHA AND GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR FOR PHAGOCYTOSIS OF CRYPTOCOCCUS-NEOFORMANS [J].
COLLINS, HL ;
BANCROFT, GJ .
EUROPEAN JOURNAL OF IMMUNOLOGY, 1992, 22 (06) :1447-1454
[30]   STEROL COMPOSITIONS AND SUSCEPTIBILITIES TO AMPHOTERICIN-B OF ENVIRONMENTAL CRYTOCOCCUS NEOFORMANS ISOLATES ARE CHANGED BY MURINE PASSAGE [J].
CURRIE, B ;
SANATI, H ;
IBRAHIM, AS ;
EDWARDS, JE ;
CASADEVALL, A ;
GHANNOUM, MA .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1995, 39 (09) :1934-1937
12345678910